Jaguar Health's stock surged 32% due to progress in its rare pediatric disease drug crofelemer and a very limited number of shares available after a recent reverse stock split. The company is advancing toward a pivotal regulatory filing for microvillus inclusion disease (MVID), with a new drug application expected by mid-2027. Despite the rally, the stock remains volatile due to its small float and ongoing risks of dilution from future fundraising. Investors should watch updates on regulatory designations and clinical progress, as setbacks could sharply impact the stock price.
Jaguar Health's stock surged 32% following rare-disease pipeline news and a thin post-split float. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 25, 2026 20:42 WIB: out of 100 priced US health stocks, 35 rose and 64 fell today. Notable movers include MESO at USD 15.23 with a -1.61% change, DNA at USD 10.09 down 1.56%, and TXG at USD 82.81 down 1.55%, with typical hold times ranging from 9 to 94 days and mixed buy/sell order activity.
Ivanhoe Electric's Santa Cruz Copper Mining Project in Arizona has strong economic potential, according to a recent Preliminary Feasibility Study. The project requires $1.43 billion in initial capital and expects low operating costs of $1.47 per poun...
Westlake, a global chemical and building materials company, has a revised analyst price target indicating a 46.27% potential upside from its current stock price. Institutional investors like Bank of America and others are increasing their holdings, r...
PayPal's stock rose following its announcement of a new strategic partnership with Meta Platforms, integrating AI-powered shopping across its merchant network. Deutsche Bank increased its price target for PayPal to $55 from $50, signaling potential u...
Assured Guaranty Ltd. (NYSE: AGO) saw its stock price pressured to a new 52-week low of $68.04 despite a recent upgrade to "Buy" by Roth Capital. The company is involved in the financial restructuring of Brightline Florida, where a subsidiary insured...
Home Depot's stock has declined nearly 29% in the past year, yet the company remains moderately undervalued, trading at 19.5 times its EPS guidance with a 3.19% dividend yield. Its strategic focus on professional customers, fast delivery, and AI inve...
